Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Previous studies have confirmed the great potential of quantitative fluorescence molecular
endoscopy (qFME) when looking at additional lesion detection initially missed by
high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.